Emodin promotes the recovery of rheumatoid arthritis by regulating the crosstalk between macrophage subsets and synovial fibroblast subsets.

大黄素通过调节巨噬细胞亚群和滑膜成纤维细胞亚群之间的相互作用来促进类风湿性关节炎的恢复

阅读:14
作者:Cheng Lianying, Rong Xiaofeng
BACKGROUND: To study the relationships among emodin, synovial fibroblasts (FLSs), and macrophages (STMs) to provide guidance for the use of emodin in rheumatoid arthritis (RA) treatment. METHODS: RA clinical samples from patients with different pathological processes were collected, and the correlations between the subsets of FLSs and STMs and pathological processes were analyzed via flow cytometry. In vitro experimental methods such as enzyme linked immunosorbent assay (ELISA), Western blotting, Transwell assays, CCK-8 assays and cell coculture were used to assess cell proliferation, migration and secretion of inflammatory factors. A collagen-induced arthritis mouse model was constructed to investigate the therapeutic potential of emodin in RA by flow cytometry, micro-CT and staining. RESULTS: Unique subsets of FLSs and STMs, namely, FAPα(+)THY1(-) FLSs, FAPα(+)THY1(+) FLSs, and MerTK(pos)TREM2(high) STMs, were identified in synovial tissues from RA patients. The number of MerTK(pos)TREM2(high) STMs was negatively correlated with the degree of damage in RA, while the number of FAPα(+)THY1(-) FLSs was positively correlated with damage. On the one hand, emodin promoted the aggregation of MerTKposTREM2high STMs. Moreover, MerTK(pos)TREM2(high) STM-mediated secretion of exosomes was promoted, which can inhibit the secretion of pro-inflammatory factors by FAPα(+)THY1(+) FLSs and promote the secretion of anti-inflammatory factors by FAPα(+)THY1(+) FLSs, thereby inhibiting FAPα(+)THY1(-)FLS proliferation and migration, improving the local immune microenvironment, and inhibiting RA damage. CONCLUSION: Emodin was shown to regulate the aggregation of STM subsets and exosome secretion, affecting the secretion, proliferation and migration of inflammatory factors in FLS subsets, and ultimately achieving good therapeutic efficacy in RA patients, suggesting that it has important clinical value.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。